首页> 美国卫生研究院文献>Frontiers in Oncology >Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status

【2h】

Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status

机译：用不同PD-L1表达状态作为转移性非小细胞肺癌的一线治疗atezolizumab与化疗的成本效果分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

AI期刊论文写作 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 Frontiers in Oncology
作者
Guoqiang Liu; Shuo Kang; Xinchen Wang; Fangjian Shang;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 11
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
atezolizumab; non-small-cell lung cancer; cost-effectiveness; chemotherapy; first-line treatment;

机译：atezolizumab;非小细胞肺癌;成本效益;化疗;一线治疗;

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive ( 50%) metastatic squamous and non-squamous non-small cell lung cancer in France [J] . Chouaid Christos, Bensimon Lionel, Clay Emilie, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2019,第期

机译：PEMBLOLIZUMAB的成本效益分析与法国PD-L1阳性（＆gt.50％）转移性鳞状和非鳞状非小细胞肺癌的第一线治疗的一线治疗方法分析
2. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater [J] . Longjiang She, Huabin Hu, Mengting Liao, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2019,第期

机译：PEMBROLIZUMAB与化疗的成本效果分析作为局部晚期或转移性非小细胞肺癌的一线治疗，PD-L1肿瘤比例得分1％或更大
3. Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels [J] . Weng Xiuhua, Luo Shaohong, Lin Shen, Oncology Research . 2020,第2期

机译：PEMBROLIZUMAB与化疗的成本实用性分析作为具有不同PD-L1表达水平转移性非小细胞肺癌的一线治疗
4. Is High-Dose Chemotherapy Plus Stem-Cell Transplant the Standard Treatment for Patients Failing First-Line Chemotherapy for Metastatic Germ Cell Tumor? [C] . Christian Kollmannsberger, Lawrence Einhorn, Craig Nichols Genitourinary Cancers Symposium. . 2014

机译：高剂量化疗加干细胞移植对转移细胞肿瘤的一线化疗失败的患者的标准治疗吗？
5. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
6. OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer [O] . Feng Wen, Hanrui Zheng, Pengfei Zhang, 2018

机译：基于OPTIMAL和ENSURE试验的厄洛替尼与化疗联合治疗亚洲非鳞状非小细胞肺癌一线患者的成本效益分析
7. CN5 - COST-EFFECTIVENESS OF PEMBROLIZUMAB VERSUS STANDARD-OF-CARE CHEMOTHERAPIES FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE (≥50) METASTATIC NON-SMALL CELL LUNG CANCER IN FRANCE [O] . C. Chouaid, L. Bensimon, E. Clay, 2018

机译：CN5 - Pembrolizumab的成本效益与法国PD-L1阳性（≥50％）转移性非小细胞肺癌的一线治疗的护理标准化学疗法

Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status

著录项

引文网络

相似文献

相关主题

期刊订阅